Literature DB >> 21344263

The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.

Marco Volante1, Luisella Righi, Alfredo Berruti, Guido Rindi, Mauro Papotti.   

Abstract

Neuroendocrine neoplasms (NEN) develop in many organs, and although they share some pathological and clinical features, significant differences do exist among different tumor types and locations. The correct classification of NENs is based on the recently published WHO classification according to the various locations, and is relevant for the appropriate treatment in each group. The apparently easy diagnostic categorization in well-differentiated NENs, called neuroendocrine tumors, and poorly differentiated NENs, called neuroendocrine carcinomas, is complicated by the existence, among others, of different terminologies, morphological criteria of malignancy, combined exocrine-endocrine tumors, as well as of heterogeneous diagnostic, prognostic, and predictive markers. The present paper is an overview of the most frequently asked questions and an attempt to provide practical answers related to NEN diagnosis in the daily pathology work.

Entities:  

Mesh:

Year:  2011        PMID: 21344263     DOI: 10.1007/s00428-011-1060-7

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  48 in total

1.  Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

Authors:  David S Klimstra; Irvin R Modlin; N Volkan Adsay; Runjan Chetty; Vikram Deshpande; Mithat Gönen; Robert T Jensen; Mark Kidd; Matthew H Kulke; Ricardo V Lloyd; Cesar Moran; Steven F Moss; Kjell Oberg; Dermot O'Toole; Guido Rindi; Marie E Robert; Saul Suster; Laura H Tang; Chin-Yuan Tzen; Mary Kay Washington; Betram Wiedenmann; James Yao
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  CDX2 as a marker of intestinal EC-cells and related well-differentiated endocrine tumors.

Authors:  Stefano La Rosa; Elena Rigoli; Silvia Uccella; Anna Maria Chiaravalli; Carlo Capella
Journal:  Virchows Arch       Date:  2004-07-29       Impact factor: 4.064

Review 3.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

4.  The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.

Authors:  Alfredo Berruti; Enrico Bollito; Cecilia M Cracco; Marco Volante; Giovannino Ciccone; Francesco Porpiglia; Mauro Papotti; Roberto Mario Scarpa; Luigi Dogliotti
Journal:  Prostate       Date:  2010-05-15       Impact factor: 4.104

5.  Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma.

Authors:  Alessandro Sciarra; Salvatore Monti; Vincenzo Gentile; Gianna Mariotti; Antonio Cardi; Giuseppe Voria; Rossana Lucera; Franco Di Silverio
Journal:  Prostate       Date:  2003-05-15       Impact factor: 4.104

Review 6.  The diagnosis and medical management of advanced neuroendocrine tumors.

Authors:  Gregory A Kaltsas; G Michael Besser; Ashley B Grossman
Journal:  Endocr Rev       Date:  2004-06       Impact factor: 19.871

7.  Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.

Authors:  James C Yao; Alexandria T Phan; David Z Chang; Robert A Wolff; Kenneth Hess; Sanjay Gupta; Carmen Jacobs; Jeannette E Mares; Andrea N Landgraf; Asif Rashid; Funda Meric-Bernstam
Journal:  J Clin Oncol       Date:  2008-09-10       Impact factor: 44.544

8.  Prognostic factors influencing survival from metastatic (stage IV) gastroenteropancreatic well-differentiated endocrine carcinoma.

Authors:  Cosimo Durante; Houda Boukheris; Clarisse Dromain; Pierre Duvillard; Sophie Leboulleux; Dominique Elias; Thierry de Baere; David Malka; Jean Lumbroso; Joël Guigay; Martin Schlumberger; Michel Ducreux; Eric Baudin
Journal:  Endocr Relat Cancer       Date:  2009-02-24       Impact factor: 5.678

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064

10.  Continuous 5-fluorouracil infusion plus long acting octreotide in advanced well-differentiated neuroendocrine carcinomas. A phase II trial of the Piemonte oncology network.

Authors:  Maria P Brizzi; Alfredo Berruti; Anna Ferrero; Enrica Milanesi; Marco Volante; Federico Castiglione; Nadia Birocco; Sebastiano Bombaci; Davide Perroni; Benedetta Ferretti; Oscar Alabiso; Libero Ciuffreda; Oscar Bertetto; Mauro Papotti; Luigi Dogliotti
Journal:  BMC Cancer       Date:  2009-11-03       Impact factor: 4.430

View more
  7 in total

1.  Mixed adenoneuroendocrine carcinoma in the stomach: a case report with a literature review.

Authors:  Ki Hyun Kim; Hyun Jung Lee; Si Hak Lee; Sun-Hwi Hwang
Journal:  Ann Surg Treat Res       Date:  2018-04-30       Impact factor: 1.859

2.  Histologically Proven Bronchial Neuroendocrine Tumors in MEN1: A GTE 51-Case Cohort Study.

Authors:  P Lecomte; C Binquet; M Le Bras; A Tabarin; C Cardot-Bauters; F Borson-Chazot; C Lombard-Bohas; E Baudin; B Delemer; M Klein; B Vergès; T Aparicio; E Cosson; A Beckers; Ph Caron; O Chabre; Ph Chanson; H Du Boullay; I Guilhem; P Niccoli; V Rohmer; J Guigay; C Vulpoi; J Y Scoazec; P Goudet
Journal:  World J Surg       Date:  2018-01       Impact factor: 3.352

Review 3.  Vascular endothelial growth factor (VEGF) pathway and neuroendocrine neoplasms (NENs): prognostic and therapeutic considerations.

Authors:  Omar Abdel-Rahman
Journal:  Tumour Biol       Date:  2014-09-18

Review 4.  Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.

Authors:  Omar Abdel-Rahman; Mona Fouad
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-03       Impact factor: 4.553

5.  Proposal for a standardized pathology report of gastroenteropancreatic neuroendocrine tumors: prognostic significance of pathological parameters.

Authors:  Mee-Yon Cho; Jin Hee Sohn; So Young Jin; Hyunki Kim; Eun Sun Jung; Mi-Jung Kim; Kyoung-Mee Kim; Woo Ho Kim; Joon Mee Kim; Yun Kyung Kang; Joon Hyuk Choi; Dae Young Kang; Youn Wha Kim; Eun Hee Choi
Journal:  Korean J Pathol       Date:  2013-06-25

Review 6.  What Is New in the 2017 World Health Organization Classification and 8th American Joint Committee on Cancer Staging System for Pancreatic Neuroendocrine Neoplasms?

Authors:  Jooae Choe; Kyung Won Kim; Hyoung Jung Kim; Dong Wook Kim; Kyu Pyo Kim; Seung-Mo Hong; Jin-Sook Ryu; Sree Harsha Tirumani; Katherine Krajewski; Nikhil Ramaiya
Journal:  Korean J Radiol       Date:  2018-12-27       Impact factor: 3.500

7.  Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.

Authors:  Alfredo Berruti; Nicola Fazio; Anna Ferrero; Maria Pia Brizzi; Marco Volante; Elisabetta Nobili; Lucia Tozzi; Lisa Bodei; Mirella Torta; Antonio D'Avolio; Adriano Massimiliano Priola; Nadia Birocco; Vito Amoroso; Guido Biasco; Mauro Papotti; Luigi Dogliotti
Journal:  BMC Cancer       Date:  2014-03-14       Impact factor: 4.430

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.